MCM2 and neoplasm: Finally, 34 meningiomas, showing MCM2 immunostaining in 20–90% cells, were IHC-G3 (MCM2 +) (Fig. 3); 17 of these cases had concurrent ACADL immunostaining in 10–80% tumor cells.